Revatio Portal-Pulmonary Arterial Hypertension Trial

Summary

The investigators propose the first prospective, double blind, randomized controlled trial of treatment for pulmonary arterial hypertension (PAH) related to underlying portal hypertension. Specifically the investigators will evaluate the potential efficacy and safety of sildenafil (Revatio) in a 16 week blinded, multicentre study.

Timeline

Start

2012-11-14

Primary completion

2017-10-30

Completion

2019-05-14

Drugs

Indications